Efficacy of adjuvant chemotherapy after complete resection of pulmonary metastasis from colorectal cancer

YUKI OKAZAKI\textsuperscript{1}, MASATSUNE SHIBUTANI\textsuperscript{1}, EN WANG\textsuperscript{1}, HISASHI NAGAHARA\textsuperscript{1}, TATSUNARI FUKUOKA\textsuperscript{1}, YASUHITO ISEKI\textsuperscript{1}, KIYOSHI MAEDA\textsuperscript{2}, KOSEI HIRAKAWA\textsuperscript{1} and MASAICHI OHIRA\textsuperscript{1}

\textsuperscript{1}Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585; \textsuperscript{2}Department of Gastroenterological Surgery, Osaka City General Hospital, Miyako-ku, Osaka 534-0021, Japan

Received March 29, 2021; Accepted July 19, 2021

DOI: 10.3892/mco.2021.2367

Abstract. The most effective treatment for pulmonary metastasis from colorectal cancer (CRC) is complete resection. However, as the recurrence rate after resection of the pulmonary metastases from CRC is high, postoperative adjuvant chemotherapy is often performed in clinical practice. The purpose of the present study was to evaluate the efficacy and safety of single-agent adjuvant chemotherapy after resection of pulmonary metastasis from CRC. The medical records of 16 patients who underwent the first complete resection of pulmonary metastasis from CRC were retrospectively reviewed. A total of eight patients were treated with single-agent adjuvant chemotherapy after resection of pulmonary metastasis, and oral fluoropyrimidines were selected in all regimens. As a result, the relapse-free survival rate after resection of pulmonary metastasis in the group that received postoperative adjuvant chemotherapy was significantly improved in comparison with the group treated with surgery alone. In the subgroup analysis, patients who benefited from postoperative adjuvant chemotherapy in some high-risk groups were selected, including patients with a high tumor stage or poor immunological status. In conclusion, single-agent adjuvant chemotherapy after resection of pulmonary metastasis from CRC was effective for reducing the risk of recurrence and was safe to administer. In addition, certain risk factors may identify patients who would receive more benefit from postoperative adjuvant chemotherapy after resection of pulmonary metastasis from CRC.

Correspondence to: Dr Masatsune Shibutani, Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
E-mail: fbxbj429@ybb.ne.jp

Abbreviations: CRC, colorectal cancer; RFS, relapse-free survival; RDI, relative dose intensity; CEA, carcinoembryonic antigen; NLR, neutrophil-to-lymphocyte ratio; TILs, tumor-infiltrating lymphocytes; CD, cluster of differentiation; HR, hazard ratio; CI, confidence interval

Key words: adjuvant chemotherapy, pulmonary metastasis, colorectal cancer, complete resection, fluoropyrimidines

Introduction

Pulmonary metastasis of colorectal cancer (CRC) is the second-most frequent type of metastasis after liver metastasis and has been reported to occur in 10-29% patients of CRC (I-7). Thus, the establishment of a treatment strategy for pulmonary metastasis from CRC is important. The resection of metastasis, radiofrequency ablation, systemic drug therapy and radiation treatments have been applied in the treatment of pulmonary metastasis from CRC. However, unlike other cancers, in CRC, there is a great deal of evidence to support that complete resection of metastasis leads to an improved prognosis in comparison to other treatments, including chemotherapy (7-10); thus, resection of pulmonary metastasis is considered the most effective treatment for metastasis from CRC and has been generally accepted as the only potentially curative treatment (9-14). However, it is difficult to say that surgery alone is a sufficient treatment, because the 5-year survival rate after complete resection of pulmonary metastasis from CRC is only 30-60% (15,16).

In clinical practice, adjuvant chemotherapy is often performed after resection of pulmonary metastasis from CRC and its effectiveness has been reported a number of times (17,18). However, the efficacy and safety of adjuvant chemotherapy after resection of pulmonary metastasis remain controversial, because its effectiveness has not been reported in any large clinical trials and the optimal regimen has not been described. The purpose of this study was to evaluate the efficacy or safety of single-agent adjuvant chemotherapy after complete resection of pulmonary metastasis from CRC.

Materials and methods

Patients and therapy. We retrospectively reviewed the medical records of 16 patients who underwent complete macroscopic and microscopic (R0) resection of pulmonary metastasis from CRC at Osaka City University Hospital between April 1998 and October 2019. All patients enrolled in this study had undergone resection of pulmonary metastasis for the first time. In all patients, the primary tumors were resected before surgical treatment for pulmonary metastasis. After the operation for primary tumor, contrast-enhanced computed tomography (CT) was performed routinely every six months. The details of...
pulmonary metastases and the presence or absence of other distant metastases were evaluated by contrast-enhanced CT. Patients who had extrapulmonary metastasis were excluded from this study. It was defined that the pulmonary metastasis found at the resection of primary tumor as synchronous metastasis and the pulmonary metastasis found after the resection of primary tumor as metachronous metastasis.

Eight patients were treated with single-agent adjuvant chemotherapy after resection of pulmonary metastasis and oral fluoropyrimidines was selected in all regimens. The other 8 patients were treated with the resection of pulmonary metastasis alone. The administration period of postoperative single-agent adjuvant chemotherapy was 6 months. The decision as to whether or not postoperative adjuvant chemotherapy should be administered, and the selection of the regimen was at the discretion of the treating physician. We evaluated the correlation between relapse-free survival (RFS) rate after the first complete resection of pulmonary metastasis from CRC and postoperative adjuvant chemotherapy.

The feasibility of postoperative adjuvant chemotherapy was evaluated to calculate completion rate and relative dose intensity (RDI) and to investigate adverse events. Adverse events were graded using the Common Terminology Criteria for Adverse Events version 5.0 (19).

Classification of patients according to risk factors. In addition, a subgroup analysis of patients who were divided according to each clinicopathological factor was performed. We divided the patients into 2 groups according to sex, age and the risk (high or low) of some clinicopathological factors that were reported to be associated with the prognosis after resection of pulmonary metastasis of CRC. The clinicopathological factors included the primary T/N classification, as defined by the Union for International Cancer Control 8th edition (20,21), the timing of metastasis (metachronous or synchronous) (20,22), number of metastases (13,23), diameter of the metastatic tumors (23) and the carcinoembryonic antigen (CEA) level before the resection of pulmonary metastases (13,14,24,25).

We also included the immunological prognostic factors for CRC that we have reported (26). These factors were the neutrophil-to-lymphocyte ratio (NLR), as a systemic inflammatory marker (27-29), and the density of tumor-infiltrating lymphocytes (TILs), which reflects the immunological status in the tumor microenvironment (26,30,31).

According to previous reports, patients with a CEA level of <5.0 mg/dl were classified into the CEA Low-group and those with a CEA level of ≥5.0 mg/dl were classified into the CEA High-group (14,23-25).

The NLR was calculated from a blood sample obtained within 2 weeks before pulmonary surgery by dividing the absolute neutrophil count by the absolute lymphocyte count. Based on the median value, patients were classified into the NLR-High or NLR-Low groups.

We set cluster of differentiation (CD)3 as the pan-T cell marker and CD8 as the cytotoxic T cell marker. Regarding the immunohistochemistry protocol of CD3/CD8, all of the resected specimens of the pulmonary metastases from CRC were fixed in 10% buffered formalin and embedded in paraffin. Immunohistochemical staining was performed on 4-μm-thick sections. All of the sections were deparaffinized in xylene and dehydrated in decreasing concentrations of ethanol. The sections were then subjected to endogenous peroxidase blocking in 1% H2O2 solution in methanol for 15 min. Antigen retrieval was performed by autoclaving the sections at 105°C for 15 min in Dako Target Retrieval Solution (Dako; Agilent Technologies, Inc.). The serum blocking was performed with 10% normal rabbit serum for 10 min. All of the sections were labeled with the peroxidase-labeled streptavidin for 5 min. The 10% normal rabbit serum, biotin-labeled rabbit anti-mouse antibody and peroxidase-labeled streptavidin were included in the Histofine SAB-PO(M) kit (Nichirei Biosciences, Inc.) and used according to the protocol of the manufacturer. Detection was performed with the 3,3-diaminobenzidine tetrahydrochloride kit (Histofine Simple Stain kit; Nichirei Biosciences, Inc.). All of the sections were counterstained with hematoxylin, dehydrated, cleared and mounted on glass coverslips.

Based on the approach in a previous report, the number of CD3+TILs/CD8+TILs at the invasive margin of the pulmonary metastases was counted in 5 randomly selected fields at a magnification of x400. The mean of the 5 values obtained was then used for the analysis (26).

To determine the appropriate cut-off value, we performed a receiver operating characteristic curve analysis. Based on the cut-off values, patients were classified into the TIL-high or TIL-low groups.

The association between RFS rate after resection of pulmonary metastasis and postoperative adjuvant chemotherapy was evaluated according to each risk factor.

Statistical analysis. Fisher's exact test and Mann-Whitney U test were used to analyze the significance of the association among the background factors between surgery alone and adjuvant chemotherapy. RFS was defined as the interval between the date of resection of pulmonary metastasis and the date of the diagnosis of the first recurrence, death from any cause or last follow-up. Survival curves were made using the Kaplan-Meier method. Differences in survival curves were assessed using the log-rank test. A multivariate Cox proportional hazards model was used to evaluate the prognostic factors associated with the RFS. The factors with P-values of <0.10 on the univariate analysis were included in the multivariate analysis.

All statistical analyses were performed using JMP 14.2.0 (SAS Institute). P-values of <0.05 were considered to indicate statistical significance.

Ethical considerations. This retrospective study was approved by the Ethics Committee of Osaka City University (approval no. 2020-026) and conducted in accordance with the Declaration of Helsinki. All patients provided their written informed consent.

Results

Patient characteristics. The patient characteristics are summarized in Table I. The study cohort included
The correlation between RFS rate and postoperative adjuvant chemotherapy. In the group that received postoperative adjuvant chemotherapy, RFS rate was significantly improved in comparison to the surgery alone group (P=0.024) (Fig. 1).

Cut-off value for the number of positive TILs. The number of positive TILs, which was a continuous variable, was used as the test variable and the occurrence of recurrence after the complete resection of pulmonary metastases was used as the state variable. When the cut-off value for the number of positive TILs was investigated using the ROC curve, the appropriate cut-off value for the CD3+ TILs was 13.6 (sensitivity of 63.6%; specificity of 100.0%) (Fig. 2A). Using the ROC curve in the same manner, the cut-off value for the CD8+ TILs was set at 21.0 (sensitivity of 100.0%; specificity of 40.0%) (Fig. 2B). With each of these values set as the cut-off value, the patients were classified into respective high and low groups.

Evaluation of prognostic factors for RFS. The correlation was evaluated between RFS and the prognostic factors, such as sex, the timing of the detection of metastasis, the number of pulmonary metastases, the location of pulmonary metastasis, the size of pulmonary metastasis, the CEA value before resection of pulmonary metastasis, whether or not postoperative adjuvant chemotherapy had been performed, the NLR and the CD3/CD8+ TIL density. According to a univariate analysis, the RFS after resection of pulmonary metastasis in the male group, the ≥2 pulmonary metastases group, the surgery alone group and the low-CD3+TIL group was significantly shorter than in the female group, the single pulmonary metastasis group, the adjuvant chemotherapy group and the high-CD3+TIL group (P=0.044, P=0.007, P=0.028, P=0.019, respectively). The multivariate analysis indicated that the number of pulmonary metastases, and the postoperative adjuvant chemotherapy and the density of CD3+ TILs were independent prognostic factors for RFS (P=0.001, P=0.002, P=0.010, respectively) (Table II).

Feasibility and adverse events in patients who received postoperative adjuvant chemotherapy. The completion rate of the 8 patients who received adjuvant chemotherapy was 100.0% and the median RDI of adjuvant chemotherapy in these 8 patients was 100.0%. Some adverse events were occurred, including fatigue (n=2), hand and foot syndrome (n=1) and oral mucositis (n=1). However, no patients experienced grade 3-5 adverse events (Table III).
Table I. Association of backgrounds between surgery alone and adjuvant chemotherapy.

| Preoperative patient characteristics (n=16) | Surgery alone (n=8) (%) | Adjuvant chemotherapy (n=8) (%) | P-value |
|-------------------------------------------|------------------------|-------------------------------|---------|
| Sex, n (%)                                |                        |                               |         |
| Male                                      | 3 (37.5)               | 7 (87.5)                      | 0.039   |
| Female                                    | 5 (62.5)               | 1 (12.5)                      |         |
| Median age, years (range)                 | 74 (61-84)             | 66.5 (57-77)                  | 0.247   |
| Location of primary tumor, n (%)          |                        |                               |         |
| Right colon                               | 0 (0)                  | 2 (25.0)                      | 0.131   |
| Left colon and rectum                     | 8 (100)                | 6 (75.0)                      |         |
| Primary T status, n (%)                   |                        |                               |         |
| ≤T3                                       | 5 (62.5)               | 6 (75.0)                      | 0.59    |
| T4                                        | 3 (37.5)               | 2 (25.0)                      |         |
| Lymph node metastasis of primary tumor, n (%) |            |                               |         |
| N0                                        | 3 (37.5)               | 4 (50.0)                      | 0.614   |
| ≥N1                                       | 5 (62.5)               | 4 (50.0)                      |         |
| Histological type of primary tumor, n (%) |                        |                               |         |
| Well/Moderately differentiated adenocarcinoma | 8 (100)               | 8 (100)                      | >0.999  |
| Poorly differentiated/mucinous adenocarcinoma | 0 (0)                 | 0 (0)                         |         |
| Detection of pulmonary metastases, n (%)  |                        |                               |         |
| Metachronous                              | 5 (62.5)               | 5 (62.5)                      | >0.999  |
| Synchronous                               | 3 (37.5)               | 3 (37.5)                      |         |
| History of resection of liver metastases before the resection pulmonary metastases, n (%) |        |                               |         |
| No                                        | 4 (50.0)               | 6 (75.0)                      | 0.302   |
| Yes                                       | 4 (50.0)               | 2 (25.0)                      |         |
| History of chemotherapy for the pulmonary metastases before the resection pulmonary metastases, n (%) |        |                               |         |
| No                                        | 7 (87.5)               | 6 (75.0)                      | 0.521   |
| Yes                                       | 1 (12.5)               | 2 (25.0)                      |         |
| Location of pulmonary metastases, n (%)   |                        |                               |         |
| One lung field                            | 7 (87.5)               | 8 (100)                       | 0.302   |
| Both lung fields                          | 1 (12.5)               | 0 (0)                         |         |
| Number of pulmonary metastases, n (%)     |                        |                               |         |
| 1                                         | 4 (50.0)               | 6 (75.0)                      | 0.302   |
| ≥2                                        | 4 (50.0)               | 2 (25.0)                      |         |
| Maximum diameter of pulmonary metastases, n (%) |            |                               |         |
| <20 mm                                     | 4 (50.0)               | 7 (87.5)                      | 0.106   |
| ≥20 mm                                     | 4 (50.0)               | 1 (12.5)                      |         |
| Method of resection of pulmonary metastases, n (%) |        |                               |         |
| Segmentectomy                             | 7 (87.5)               | 8 (100)                       | 0.302   |
| Lobectomy                                 | 1 (12.5)               | 0 (0)                         |         |
| CEA level before resection of pulmonary metastases, n (%) |        |                               |         |
| ≤5 ng/ml                                   | 5 (62.5)               | 6 (75.0)                      | 0.59    |
| >5 ng/ml                                   | 3 (37.5)               | 2 (25.0)                      |         |
| Neutrophil-to-lymphocyte ratio before the resection of pulmonary metastases, n (%) |        |                               |         |
| ≤1.89                                      | 2 (25.0)               | 6 (75.0)                      | 0.046   |
| >1.89                                      | 6 (75.0)               | 2 (25.0)                      |         |

CEA, carcinoembryonic antigen.
The effectiveness of postoperative adjuvant chemotherapy for suppressing recurrence according to each risk factor.

In the subgroups of patients who were positive for lymph node metastasis of the primary tumor, patients with 2 or more pulmonary metastases and patients with a low density of CD3+ TILs or a low density of CD8+ TILs at the site of pulmonary metastasis, postoperative adjuvant chemotherapy significantly reduced the risk of recurrence in comparison to surgery alone (P=0.017; 0.049; 0.025; 0.008, respectively). In the subgroups of patients with a high NLR(>1.89), postoperative adjuvant chemotherapy tended to reduce the risk of recurrence in comparison to surgery alone (P=0.092) (Fig. 3).

Discussion

In cases of distant metastasis from CRC, unlike other cancers, the complete resection of distant metastasis is reported to improve the prognosis in comparison to chemotherapy. Thus, the resection of metastasis from CRC has been performed positively (7-10). However, the recurrence rate after complete resection of distant metastasis from CRC was comparatively high, thus, postoperative adjuvant chemotherapy has been often performed in clinical practice.

Regarding adjuvant chemotherapy after complete resection of pulmonary metastasis from CRC, some studies reported that it was effective for suppressing recurrence and prolonging the prognosis (17,18). On the other hand, other studies reported that it was not effective (32,33). The reason why the results can be different between cohorts for the adjuvant chemotherapy after resection of pulmonary metastases of colorectal cancer was considered to be the difference of regimen. In the existing reports, the single-agent adjuvant chemotherapy regimen and the combination adjuvant chemotherapy regimen were evaluated simultaneously, and the percentage of these regimen were different in each cohort. In addition, there have

Table II. Correlations between relapse-free survival and clinicopathological factors.

| Clinicopathological factors                      | Univariate analysis | Multivariate analysis |
|-------------------------------------------------|---------------------|----------------------|
|                                                  | HR  | 95% CI   | P-value | HR  | 95% CI   | P-value |
| Sex (Male vs. Female)                           | 0.268 | 0.067-0.964 | 0.044   | 1.477 | 0.271-10.88 | 0.655   |
| Detection of pulmonary metastases               | 0.490 | 0.107-1.703 | 0.272   |
| Synchronous vs. Metachronous                    | 6.984 | 0.325-72.95 | 0.172   |
| Location of pulmonary metastases                | 6.559 | 1.690-31.63 | 0.007   | 30.93 | 3.193-1205.6 | 0.001   |
| One lung field vs. both lung fields              | 1.328 | 0.347-4.418 | 0.656   |
| Number of pulmonary metastases                  | 1.434 | 0.373-4.796 | 0.575   |
| 1 vs. ≥2                                        | 0.234 | 0.050-0.855 | 0.028   | 0.026 | 0.001-0.285 | 0.002   |
| Maximum diameter of pulmonary metastases        | 1.448 | 0.434-5.043 | 0.542   |
| <20.0 mm vs. ≥20.0 mm                           | 4.402 | 1.282-17.32 | 0.019   | 10.93 | 7.32-160.5 | 0.001   |
| CEA level before resection of pulmonary metastases | 5.0 ng/ml vs. >5.0 ng/ml | 1.309 | 0.347-4.418 | 0.656   |
| Treatment performed to pulmonary metastases     | 6.559 | 1.690-31.63 | 0.007   | 30.93 | 3.193-1205.6 | 0.001   |
| Surgery alone vs. single-agent adjuvant chemotherapy after resection | 1.328 | 0.347-4.418 | 0.656   |
| NLR before resection of pulmonary metastases    | 1.448 | 0.434-5.043 | 0.542   |
| ≤18.9 vs. >18.9                                 | 4.402 | 1.282-17.32 | 0.019   | 10.93 | 7.32-160.5 | 0.001   |
| Density of CD3+ TILs of pulmonary metastasis    | 5.0 ng/ml vs. >5.0 ng/ml | 1.309 | 0.347-4.418 | 0.656   |
| >13.6 vs. ≤13.6                                 | 3.509 | 0.667-64.54 | 0.158   |
| Density of CD8+ TILs of pulmonary metastasis    | 5.0 ng/ml vs. >5.0 ng/ml | 1.309 | 0.347-4.418 | 0.656   |
| >21.0 vs. ≤21.0                                 | 5.0 ng/ml vs. >5.0 ng/ml | 1.309 | 0.347-4.418 | 0.656   |
| HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; NLR, neutrophil-to-lymphocyte ratio; TILs, tumor-infiltrating lymphocytes.

Table III. Feasibility and adverse event of postoperative single-agent adjuvant chemotherapy in eight patients.

| Parameter                                | Patients |
|------------------------------------------|----------|
| Feasibility                              | 100%     |
| Completion rate, %                       | 100%     |
| Median relative dose intensity, %        | 100%     |
| (range)                                  | (75.0-100.0%) |
| Adverse event, grade 1-2, n (%)          | 2 (25.0%) |
| Fatigue                                  | 2 (25.0%) |
| Oral mucositis                           | 1 (12.5%) |
| Hand and foot syndrome                   | 1 (12.5%) |
been no reports based on the results of large clinical trials; thus, the efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from CRC has remained controversial. Therefore, in clinical practice, the indication and regimen of adjuvant chemotherapy largely depends on the judgment of the individual physician.

In this study, RFS rate was significantly improved in the group that received single-agent fluoropyrimidine adjuvant chemotherapy after resection of pulmonary metastasis. With the exception of sex and the NLR, the patient characteristics of the adjuvant chemotherapy and surgery alone groups did not differ to a statistically significant extent; thus, the postoperative adjuvant chemotherapy was correlated with the extension of the prognosis. In addition, the rate of incidences of adverse events was not high and no Grade 3-5 adverse events were occurred. Thus, the tolerability of single-agent adjuvant chemotherapy after resection of pulmonary metastasis from CRC was considered acceptable.

It has been reported that single-agent adjuvant chemotherapy was effective for suppressing recurrence not only after complete resection of primary CRC (34) but also after complete resection of hepatic metastasis from CRC (35). Similarly, in this study, in patients with pulmonary metastasis of CRC, the RFS rate of patients who received single-agent adjuvant chemotherapy with fluoropyrimidines was significantly improved. Thus, it was suggested that even single-agent adjuvant chemotherapy reduced the risk of recurrence. Additionally, single-agent adjuvant chemotherapy was associated with few adverse events and was safe to administer to patients with decreased physical strength after resection of pulmonary metastasis. Therefore, it was suggested that single-agent adjuvant chemotherapy was one of the treatment options after complete resection of pulmonary metastasis from CRC.

Okumura et al reported that the efficacy of adjuvant chemotherapy after resection of pulmonary metastasis tended to be recognized by the risk classification and limitation of the patients who are likely to benefit from postoperative adjuvant chemotherapy (36). We hypothesize that the fact that postoperative adjuvant chemotherapy was performed without considering the risk classifications and limitations of patients is one of the reasons why the prognosis was not effectively prolonged by postoperative adjuvant chemotherapy in the previous reports. Even in our small study population, we found that some subgroups of patients with risk factors of recurrence based on patient clinicopathological or immunological factors may receive more benefit from adjuvant chemotherapy after resection of pulmonary metastasis. As systemic inflammation or a poor local immune status provide a favorable environment for the development of micrometastases (37-40), the risk of recurrence after the resection of pulmonary metastases increases in high NLR patients or in low density TILs patients (26). Therefore, the risk classification according to the status of immunological biomarkers as well as the risk factors of recurrence, which have been described in previous reports, may help in the patient selection process to identify those who will most benefit from postoperative adjuvant chemotherapy.

The present study was associated with some limitations. First, this was a retrospective study with a relatively small population of patients who were treated at a single institution. A prospective study in multiple institutions with an increased number of patients is considered necessary. Second, the prognosis was only evaluated by RFS rate. This was because the chemotherapies used to treat recurrence after complete resection of pulmonary metastasis have changed over the past 20 years with the development of oxaliplatin, irinotecan and molecular targeted drugs; thus, overall survival rate was difficult to evaluate. Third, the treatment methods were not unified because the decision of whether to perform postoperative adjuvant chemotherapy was made by the attending physician. Fourth, in this study, no patients received combination adjuvant chemotherapy and the difference in the effectiveness or safety between

Figure 2. Receiver operating characteristic curves of the number of tumor-infiltrating lymphocytes and relapse-free survival status after resection of pulmonary metastases. (A) Receiver operating characteristic curve of the number of CD3+ tumor-infiltrating lymphocytes and relapse-free survival status after resection of pulmonary metastases. Area under the curve=0.764; 95% confidence interval=0.459-0.925; P=0.194. (B) Receiver operating characteristic curve of the number of CD8+ tumor-infiltrating lymphocytes and relapse-free survival status after resection of pulmonary metastases. Area under the curve=0.727; 95% confidence interval=0.383-0.920; P=0.117.
Figure 3. Kaplan-Meier survival curves for relapse-free survival after complete resection of pulmonary metastasis of colorectal cancer according to the single-agent postoperative adjuvant chemotherapy regimen in subgroups divided according to each clinicopathological factor. (A) Primary N status, N0. (B) Primary N status, N1-3. (C) Number of pulmonary metastases=1. (D) Number of pulmonary metastases=≥2. (E) Neutrophil-to-lymphocyte ratio ≤ median. (F) Neutrophil-to-lymphocyte ratio > median. (G) High density of CD3+ tumor-infiltrating lymphocytes group. (H) Low density of CD3+ tumor-infiltrating lymphocytes. (I) High density of CD8+ tumor-infiltrating lymphocytes. (J) Low density of CD8+ tumor-infiltrating lymphocytes.
single-agent adjuvant chemotherapy and combination adjuvant chemotherapy was not compared.

A large prospective study is necessary to identify patients who will be benefit from postoperative adjuvant chemotherapy and to determine the most effective regimen.

In conclusion, single-agent adjuvant chemotherapy after the resection of pulmonary metastasis from CRC was effective for reducing the risk of recurrence and was safe to administer. In addition, certain risk classifications based on clinicopathological factors, including immunological markers, may be useful for identifying patients who would receive more benefit from adjuvant chemotherapy after resection of pulmonary metastasis from CRC.

Acknowledgements

The authors thank Mr Brian Quinn (Japan Medical Communication, Fukuoka, Japan) for providing medical writing services.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YO designed the study, performed the statistical analysis and drafted the manuscript. MS designed the study and assisted in writing the manuscript. EW, HN, TF and YI collected the clinical data and revised the manuscript critically. YO, MS and CW confirmed the authenticity of all the raw data. KM, KH and MO assisted with designing the study and critically reviewed the manuscript. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Osaka City University (approval no. 2020-026) and all patients provided their written informed consent. All procedures performed in studies involving human participants were in accordance with the Declaration of Helsinki.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Zhang C, Tan Y and Xu H: Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer? A systematic review and meta-analysis. Int J Colorectal Dis 34: 1661-1671, 2019.

2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.

3. Mitry E, Guiri B, Cosconea S, Jooste V, Faivre J and Bouvier AM: Epidemiology, management and prognosis of colorectal cancer with lung metastases: A 30-year population-based study. Gut 59: 1383-1388, 2010.

4. Labianca R, Beretta GD, Keldani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Spadri A, Gatta G, et al: Colon cancer. Crit Rev Oncol Hematol 74: 106-133, 2010.

5. Tampellini M, Ortona A, Bellini E, Alabino I, Baratelli C, Bitossi R, Brizzi MP, Ferrero A, Spadri E, Leone F, et al: The role of lung metastasis resection in improving outcome of colorectal cancer patients: Results from a large retrospective study. Oncologist 17: 1430-1438, 2012.

6. Wang Z, Wang X, Yuan J, Zhang X, Zhou J, Lu M, Liu D, Li J and Shen L: Survival benefit of palliative local treatments and efficacy of different pharmacotherapies in colorectal cancer with lung metastasis: Results from a large retrospective study. Clin Colorectal Cancer 17: e233-e235, 2018.

7. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: Analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46 (Suppl 10): S22-S31, 2003.

8. Chua FC, Saxena A, Liauw W, Chu Fand Morris DL: Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases—a systematic review. Êur J Cancer 48: 1757-1765, 2012.

9. Koga R, Yamamoto J, Saiura A, Yamaguchi T, Hata E and Sakamoto M: Surgical resection of pulmonary metastases from colorectal cancer: Four favourable prognostic factors. Jpn J Clin Oncol 36: 643-648, 2006.

10. Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y and Fujisawa T: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 82: 254-260, 2006.

11. Kandilor D, Krömer E, Tüchler H, End A, Müller MR, Wolner E and Eckersberger F: Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 65: 909-912, 1998.

12. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducieux M, Baldeyrou P and Levassur P: Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66: 214-218, 1998.

13. Okumura S, Kondo H, Tsuibo M, Nakayama H, Asamura H, Tsuchiya R and Naruke T: Pulmonary resection for metastatic colorectal cancer: Experiences with 159 patients. J Thorac Cardiovasc Surg 112: 867-874, 1996.

14. Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Suzuki M, Takao H and Nakade M: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 124: 1007-1013, 2002.

15. Pfannschmidt J, Diemenn H and Hoffmann H: Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series. Ann Thorac Surg 84: 324-338, 2007.

16. Nakajima J: Pulmonary metastasis: Rationale for local treatments and techniques. Gen Thorac Cardiovasc Surg 58: 445-451, 2010.

17. Ippoliti S, Naito M, Naito M, Nakajima J, Akiyama J, Nakajima J, Saito Y, Koike K, Eguchi K, Tsuchiya R and Naruke T: Pulmonary resection for colorectal cancer metastases. Ann Thorac Surg 106: 421-427, 2018.
21. TNM Classification of Malignant Tumours. 8th edition. Brierley JD, Gospodarowicz MK and Wittekind C (eds.). John Wiley & Sons Ltd., New Jersey, 2017.

22. Lin BR, Chang TC, Lee YC, Lee PH, Chang KJ and Liang JT: Pulmonary resection for colorectal cancer metastases: Duration between cancer onset and lung metastasis as an important prognostic factor. Ann Surg Oncol 16: 1026-1032, 2009.

23. Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Hori H, Matsuguma H, Ikeda N, Yoshino I, Ozeki Y, et al: Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: A retrospective analysis. Ann Surg 257: 1059-1064, 2013.

24. Gonzalez M and Gervaz P: Risk factors for survival after lung metastasectomy in colorectal cancer patients: Systematic review and meta-analysis. Future Oncol 11 (2 Suppl): S31-S33, 2015.

25. Watanabe K, Nagai K, Kobayashi A, Sugito M and Saito N: Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 96: 1058-1065, 2009.

26. Okazaki Y, Shibutani M, Wang EN, Nagahara H, Fukushima H, Iseki Y, Kashiwagi S, Tanaka H, Maeda K, Hirakawa K and Ohira M: Prognostic significance of the immunological indices in patients who underwent complete resection of pulmonary metastases of colorectal cancer. In vivo 35: 1091-1100, 2021.

27. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH and Jiang WQ: Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15: 516-522, 2010.

28. Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, Chiang JM and Lin JR: Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis 27: 1347-1357, 2012.

29. Mallappa S, Sinha A, Gupta S and Chadwick SJ: Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 15: 323-328, 2013.

30. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijker K, Estrada MV, Gonzalez-Ericsson PI, et al: Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International immunoncology biomarkers working group: Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24: 235-251, 2017.

31. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijker K, Estrada MV, Gonzalez-Ericsson PI, et al: Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International immunoncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24: 311-335, 2017.

32. Imanishi M, Yamamoto Y, Hamano Y, Yamada T, Moriwaki T, Gosho M, Okumura T, Boku N, Kondo H and Hyodo I: Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: A propensity score-matched analysis. Eur J Cancer 106: 69-77, 2019.

33. Park S, Kang BW, Lee SJ, Yoon S, Chae YS, Kim JG, Lee KH, Koh SA, Song HS, Park KU, et al: Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer. Cancer Chemother Pharmacol 80: 187-193, 2017.

34. Sakamoto J, Kodaira S, Hamada C, Ito K, Machara Y, Takagi H, Sugimuchi K, Nakazato H and Ohashi Y: Meta-analysis group of the Japanese society of strategies for Cancer Research and Therapy: An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncol Rep 8: 697-703, 2001.

35. Hasegawa K, Sairua A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, et al: Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: A randomized controlled trial. PLoS One 11: e0162400, 2016.

36. Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, Yoshiya K, Higashiyama M, Hyodo I, Mori K and Kondo H: Surgical Outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann Thorac Surg 104: 979-987, 2017.

37. Shibutani M, Nagahara H, Fukutoa T, Iseki Y, Hirakawa K and Ohira M: Efficacy of adjuvant chemotherapy according to the classification of recurrence risk based on systemic inflammatory markers in patients with liver metastases of colorectal cancer. Anticancer Res 39: 5039-5045, 2019.

38. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.

39. Mantovani C, Levrà NG, Filippi AR, Novello S, Buffoni L, Ragona R and Ricardi U: Postoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: A retrospective analysis. Clin Lung Cancer 14: 194-199, 2013.

40. Chiang AC and Massagué J: Molecular basis of metastasis. N Engl J Med 359: 2814-2823, 2008.